Cardiology News / Recent Literature Review / First Quarter 2016 by Manolis, Antonis S & Anninos, Hector
53 
 
Cardiology News / Recent Literature Review / 
First Quarter 2016 
 
Antonis S. Manolis, MD, Hector Anninos, MD 
Athens University School of Medicine, Athens, Greece   
Rhythmos 2016;11(2):53-61.    
ACC 65th Annual Session: Chicago, 2-4/4/2016  
HRS 37th Annual Meeting: San Francisco, 4-7/5/16  
CardioStim/Europace: Nice, 8-11/6/2016  
Euro PCR: Paris, 17-20/5/2016  
ESC Meeting: Rome, 27-31/8/2016  
HCS Panhellenic Congress: Athens, 20-22/10/2016  
TCT Conference: Washington, DC, 29/10-2/11/2016  
AHA Scientific Sessions: New Orleans, 12-16/11/2016   
Exercise-Based Cardiac Rehabilitation Reduces the 
Risk of Cardiovascular (CV) Mortality and 
Hospital Admission and Improves Quality of Life in 
Patients With Coronary Heart Disease  
Meta-analyses of exercise-based cardiac rehabilitation 
(CR) studies (n=63) comprising 14,486 participants with 
median follow-up of 1 year indicated that CR led to a 
reduction in CV mortality (relative risk - RR: 0.74) and the 
risk of hospital admissions (RR: 0.82). There was no 
significant effect on mortality, MI, or revascularization. 
The majority of studies (14 of 20) showed higher levels of 
health-related quality of life following exercise-based CR 
compared with control subjects (Anderson L et al, J Am 
Coll Cardiol 2016;67:1-12).   
Coronary CT Angiography (CCTA), Applied Early in 
Suspected Acute Coronary Syndrome (ACS), is Safe 
and Associated with Less Outpatient Testing and 
Lower Costs. However, in the Era of hs-Troponins, it 
does not Identify more Patients with Significant CAD 
Requiring Coronary Revascularization, nor does it 
Shorten Hospital Stay or Allow for More Immediate 
Discharge from the Emergency Department (ED) 
Among 500 patients (age 54 ± 10 years, 47% women) 
with symptoms suggestive of an ACS at the ED, there was 
no difference in the primary endpoint (22 or 9% patients 
underwent coronary revascularization within 30 days in 
the CCTA group and 17 or 7% in the standard care group; 
p= NS). Discharge from the ED was not more frequent 
after CCTA (65% vs 59%, p= NS), and length of stay was 
similar (6.3 h in both groups; p= NS). The CCTA group 
had lower direct medical costs (€337 vs €511, p< 0.01) and 
less outpatient testing (10 or 4% vs 26 or 10%, p< 0.01). 
There was no difference in incidence of undetected ACS 
(Dedic A et al, J Am Coll Cardiol 2016; 67:16-26).  
Cost-Effectiveness of Transcatheter Aortic Valve 
Implantation (TAVI) with a Self-Expanding Prosthesis 
vs Surgical Aortic Valve Replacement (AVR): TAVI in 
Patients at High Risk for Complications with AVR 
Provides Important Incremental Health Benefits at 
Reasonable Incremental Costs and is an Acceptable 
Value for the U.S. Health Care System 
Relative to AVR, TAVI reduced initial length of stay 
an average of 4.4 days, decreased the need for 
rehabilitation services at discharge, and resulted in 
superior 1-month quality of life. Index admission and 
projected lifetime costs were higher with TAVI than with 
AVR (differences $11,260 and $17,849 per patient, 
respectively), whereas TAVI was projected to provide a 
lifetime gain of 0.32 quality-adjusted life-years (QALY; 
0.41 LY) with 3% discounting. Lifetime incremental cost-
effectiveness ratios were $55,090 per QALY gained and 
$43,114 per LY gained. N.B.: mean procedure costs: 
$37,920 for TAVI & $14,258 for AVR (Reynolds MR et 
al, J Am Coll Cardiol 2016;67:29-38).   
5-Year Follow-Up of SYNTAX: for Patients with 
Complex Coronary Disease, CABG Conferred a Lower 
Rate of Cardiac Death After Than PCI, and Patients 
who Had PCI with First-Generation DES were at 
Higher Risk of Fatal MI Than Those Who Had CABG  
In this cohort, there were 97 deaths after CABG and 
123 deaths after PCI at 5 years. After CABG, 49.4% of 
deaths were cardiovascular (CV), with the greatest cause 
being heart failure, arrhythmia, or other causes (24.6%), 
whereas after PCI, the majority of deaths were CV (67.5%) 
and as a result of MI (29.3%). All-cause death rates were 
not significantly different between CABG and PCI (11.4% 
vs 13.9%; p= NS), whereas there were significant 
differences for CV (5.8% vs 9.6%; p=0.008) and cardiac 
death (5.3% vs 9%; p=0.003), which were caused 
primarily by a reduction in MI-related death with CABG 
compared with PCI (0.4% vs 4.1%; p<0.0001). Treatment 
with PCI vs CABG was an independent predictor of 
cardiac death (hazard ratio: 1.55; p=0.045). The difference 
in MI-related death was mostly seen in patients with 
diabetes, 3-vessel disease, or high SYNTAX scores 
(Milojevic M et al, J Am Coll Cardiol 2016;67:42-55).   
TRANSLATE-ACS: after AMI and PCI, Patients Who 
Develop Bleeding During Dual Antiplatelet Therapy 
(DAPT) Exhibit Worse Health Status and Quality of 
Life After 6 Months Proportionate to Severity of 
Bleeding  
Of 9,290 patients with AMI treated with PCI, bleeding 
events on contemporary DAPT occurred as follows: any 
Bleeding Academic Research Consortium (BARC) 
bleeding: 24.2%; BARC 1: 9.1%; BARC 2: 13.8%; BARC 
3: 1.1%; BARC 4: 0.03%; and BARC 5: 0%. Those who 
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experienced any BARC bleeding had lower scores across 
all quality of life (QOL) domains. Any BARC bleeding 
was independently associated with 6-month QOL score 
(p< 0.0001) in a stepwise fashion with increasing BARC 
severity (Amin AP et al, J Am Coll Cardiol 2016;67:59-
65.66: 2173-2184).   
MESA (Multi-Ethnic Study of Atherosclerosis): 
Nontraditional CV Risk Markers (Coronary Artery 
Calcium-CAC Score, Ankle–Brachial Index-ABI, 
hsCRP Levels, and Family History -FH were each 
Independently Associated with Atherosclerotic CV 
Disease (ASCVD) Beyond Traditional Risk Factors 
Of 5,185 participants not prescribed statins at baseline 
(mean age 61 years; 53% women, 9.8% diabetes, 13.6% 
current smokers), after 10 years of follow-up, 320 (6.2%) 
ASCVD events occurred. CAC score, ABI, and FH were 
independent predictors of ASCVD events. CAC score 
modestly improved the discriminative ability of the risk 
estimator compared with other nontraditional risk markers 
(Yeboah J et al, J Am Coll Cardiol 2015;66:2189-2196).   
Infective Endocarditis (IE): A Systematic Search Can 
Identify the Source of Bacteremia in 3/4 of Patients 
With IE, and in >1/3 of Cases, Additional Potential 
Portals of Entry (POE) Can Be Found That Pose a Risk 
for Future Infections 
The POEs of the present IE episodes were identified in 
74% of the 318 included patients. The most frequent POE 
was cutaneous (40%). It was mainly (62% of cutaneous 
POEs) associated with health care and with intravenous 
drug use. The second most frequent POE was oral or dental 
(29%). A dental infectious focus was more often involved 
(59%) than a dental procedure (12%). POEs were 
gastrointestinal in 23% of patients. Colonic polyps were 
found in half of patients and colorectal adenocarcinomas 
in 14%. The authors advise the systematic performance of 
stomatologic examinations in patients with IE and 
performance of colonoscopy in patients ≥50 years of age 
or at high risk for colorectal cancer (Delahaye F et al, J Am 
Coll Cardiol 2016;67:151-158).   
ATRIA Study: Among Patients With Diabetes and 
Atrial Fibrillation (AF), the Duration of Diabetes is a 
More Important Predictor of Ischemic Stroke Than 
Glycemic Control  
Among 2,101 diabetic patients (40% with duration <3 
years and 60% ≥3 years at baseline) and 1,933 included in 
the hemoglobin A1c (HbA1c) analysis (46% with HbA1c 
<7%, 36% at 7%-8.9%, & 19% ≥9%), duration of diabetes 
≥3 years was associated with an increased rate of ischemic 
stroke compared with duration <3 years (hazard ratio - HR: 
1.74). The increased stroke rate was observed in older (age 
≥75 years) and younger (age <75 years) patients. Neither 
poor glycemic control (HbA1c ≥9%, HR: 1.04) nor 
moderately increased HbA1c (7-8.9%, HR: 1.21) were 
significantly associated with an increased rate of ischemic 
stroke compared with patients who had HbA1c <7% 
(Ashburner JM et al, J Am Coll Cardiol 2016;67:239-247).  
SMILE Trial: in Multivessel Non–ST-Segment 
Elevation Myocardial Infarction (NSTEMI) Patients, 
Complete 1-Stage Coronary Revascularization is 
Superior to Multistage PCI Regarding Major Adverse 
Cardiovascular/Cerebrovascular Events (MACCE)  
Among 584 patients randomly assigned to 1-stage (1S-
PCI) or multistage PCI (MS-PCI), the occurrence of the 
primary endpoint (MACCE) was significantly lower in the 
1-stage group (1S-PCI: n= 36 - 13.6% vs. MS-PCI: n = 61 
- 23.2%; hazard ratio -HR: 0.549; p = 0.004). The 1-year 
rate of target vessel revascularization was significantly 
higher in the MS-PCI group (1S-PCI: n = 22 - 8.3% vs MS-
PCI: n = 40 - 15.2%; HR: 0.522; p = 0.01). Analysis of 
cardiac death and MI showed no significant differences 
(Sardella G et al, J Am Coll Cardiol 2016; 67:264-272).   
IMPROVE-IT: In Addition to Reducing First Events 
in Patients After an ACS, Combination Therapy With 
Ezetimibe Plus Simvastatin Also Reduced Total Events 
Compared With Simvastatin Alone  
During a median 6-year follow-up, among 18,144 
patients, there were 9,545 total cardiovascular (CV) events 
(56% first and 44% subsequent events), which were 
significantly reduced by 9% with ezetimibe/simvastatin vs 
placebo/simvastatin (incidence-rate ratio - RR: 0.91; p = 
0.007), as was the composite endpoint of CV death, MI, or 
stroke (RR: 0.88; p = 0.002). The reduction in total events 
was driven by decreases in total nonfatal MI (RR: 0.87; p 
= 0.004) and total nonfatal stroke (RR: 0.77; p = 0.005) 
(Murphy SA et al, J Am Coll Cardiol 2016;67:353-361).  
MADIT-CRT Trial: Relative Wall Thickness (RWT) is 
Inversely Related to the Risk of Ventricular 
Tachycardia (VT) in Patients with Systolic Heart 
Failure (HF) and LBBB / CRT-D Conferred an 
Increase in RWT and Reduction in VT Risk  
Relative wall thickness (RWT), defined as 2 times 
posterior wall thickness divided by the left ventricular 
(LV) diastolic diameter, is a measure of LV geometry and 
may be a marker for adverse events in patients with LV 
dysfunction. In 1,260 patients with mild HF and LBBB, 
RWT was the most powerful echocardiographic measure 
for estimating the risk of VT. Patients with low RWT 
(<0.24) had 83% (p<0.001) increased risk for VT and 68% 
(p<0.001) increase in VT risk or death (VT/death). Each 
0.01-unit decrease in RWT was associated with 12% (p< 
0.001) and 10% (p< 0.001) increases in the risk of VT and 
VT/death, respectively. Cardiac resynchronization therapy 
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with defibrillator (CRT-D) was associated with a greater 
increase in RWT compared with ICD at 1 year (4.6 ± 6.8% 
vs 1.5 ± 2.7%; p < 0.001), and every 10% increase in RWT 
in CRT-D patients was associated with 34% (p = 0.027) 
and 36% (p = 0.009) reductions in the risk of subsequent 
VT and VT/death, respectively (Biton Y et al, J Am Coll 
Cardiol 2016;67:303-312).  
CYCLE Trial: IV Cyclosporine A (CsA) Immediately 
Before Primary Coronary Angioplasty Within 6 h from 
Symptom Onset in Patients With STEMI did not 
Improve Markers of Myocardial Injury, Ventricular 
Remodeling, or Clinical Outcomes, Indicating that this 
Strategy did not Prevent or Reduce Reperfusion-
Related Injury  
In 410 patients, aged 63 ± 12 years, with large STEMI 
committed to primary PCI, randomly assigned within 6 h 
of symptom onset to 2.5 mg/kg IV CsA (n=207) or control 
(n=203) groups, time from symptom onset to first ante-
grade flow was 180 ± 67 min; a median of 5 ECG leads 
showed ST-segment deviation; ~50% of MIs were 
anterior. ST-segment resolution ≥70% was found in 52% 
of CsA patients and 49% of controls (p=NS). Median hs-
cTnT on day 4 was 2,160 ng/l in CsA and 2,068 ng/l in 
controls (p=NS). The 2 groups did not differ in LV ejection 
fraction on day 4 and at 6 months. Infarct site did not 
influence CsA efficacy. There were no acute allergic 
reactions or nonsignificant excesses of 6-month mortality 
(5.7% CsA vs 3.2% controls, p=NS) or cardiogenic shock 
(2.4% CsA vs 1.5% controls, p=NS) (Ottani F et al; J Am 
Coll Cardiol 2016;67:365-374).   
Chlorthalidone: Low-Dose Chlorthalidone, 6.25 mg/d, 
is More Effective than Hydrochlorothiazide (HCTZ), 
12.5 mg/d, in Reducing Daytime, Nighttime, and Mean 
24-h Ambulatory Blood Pressure Over 4 - 12 Weeks 
with only 6.3% Hypokalemia and Can be Prescribed as 
Initial Therapy for Treatment of Hypertension, 
Whereas Low-Dose HCTZ Should no Longer be Used  
Chlorthalidone 6.25 mg/d (n=16) was compared with 
HCTZ 12.5 mg/d (n=18), or HCTZ-CR 12.5 mg (n=20) 
over 12-weeks in 54 patients with stage 1 hypertension. All 
3 treatments significantly (p < 0.01) lowered office blood 
pressure (BP) at weeks 4 and 12 from baseline. At weeks 
4 and 12, significant reductions in systolic and diastolic 24-
h ambulatory and nighttime BP (p<0.01) were observed 
with chlorthalidone but not with HCTZ. At weeks 4 (p= 
0.015) and 12 (p=0.020), nighttime systolic ambulatory BP 
was significantly lower in the chlorthalidone group than in 
the HCTZ group. The HCTZ-CR group showed a 
significant (p< 0.01) reduction in 24-h BP. All 3 treatments 
were generally safe and well tolerated (Pareek AK et al, J 
Am Coll Cardiol 2016;67:379-389).   
REACH Registry: Pulse pressure (PP), Arising as a 
Consequence of Arterial Stiffness in Patients With 
Atherosclerosis, is a Marker of Cardiovascular Disease 
Burden and Identifies Patients at Risk for Ischemic 
Events According to a Large, International Registry of 
>45,000 Participants With Established or at High Risk 
for Arterial Disease  
In a 45,087 cohort (aged 68 ± 10 years, 35% women, 
81% treated for hypertension), with mean blood pressure 
of 138 ± 19/79 ± 11 mmHg, rendering a mean PP of 49 ± 
16 mmHg, on univariate analysis, increasing PP quartile 
was associated with worse outcomes (p< 0.05). After 
adjusting for gender, age, current smoking status, history 
of hypercholesterolemia, history of diabetes, aspirin use, 
statin use, blood pressure drug use, and mean arterial 
pressure, PP quartile was still associated with all outcomes 
except all stroke and cardiovascular death (p< 0.05) 
(Selvaraj S et al, J Am Coll Cardiol 2016;67:392-403).  
In Patients With Degenerative Mitral Regurgitation 
(MR) Undergoing Surgical Repair With Annuloplasty, 
Recurrences are Low/ >Mild Early Post-Operative MR 
is Associated With Adverse Ventricular Remodeling 
and Higher Rates of Recurrent MR, Need for 
Reoperation, and Death Than in Patients With None-
To-Trivial Early Post-Operative MR  
Among 1,218 patients (mean age 64 ± 13 years, mean 
ejection fraction 63 ± 9%, 864 - 71% men), the 15-year 
incidence of recurrent MR (MR≥2) was 13.3%, mitral 
reoperation 6.9%, and overall mortality 44%. Repair 
before 1996 independently predicted MR recurrence 
(hazard ratio: 1.52). Additional determinants were: age, 
mild intraoperative residual MR, anterior leaflet prolapse, 
bileaflet prolapse, perfusion time >90 min, and lack of 
annuloplasty. Recurrence of >moderate MR was 
associated with adverse left ventricular remodeling and 
increased likelihood of late death (hazard ratio: 1.72). 
After 1996, MR recurrence decreased markedly following 
the first year after intervention (Suri RM et al, J Am Coll 
Cardiol 2016;67:488-498).  
THERMOCOOL VT Trial: Radiofrequency Ablation 
of VT is Effective in Preventing Recurrent VT and ICD 
Shocks, Reducing Hospitalizations, and Improving 
Quality of Life for ≥3 Years 
In patients (n=249; mean age 67.4 y) with sustained 
monomorphic ventricular tachycardia (VT) associated 
with coronary disease, the cardiovascular-specific adverse 
events rate was 3.9% (9 of 233) with no strokes. 
Noninducibility of targeted VT was achieved in 75.9% of 
patients. Post-ablation median hospitalization was 2 days. 
At 6 months, 62% (114 of 184) of patients had no sustained 
monomorphic VT recurrence; the proportion of patients 
with ICD shocks decreased from 81.2% to 26.8% (p< 
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0.0001); the frequency of VT in ICD patients with 
recurrences was reduced by ≥50% in 63.8% of patients; 
and quality of life improved (p< 0.001). Patient-reported 
VT remained steady for 1, 2, and 3 years at 22.7%, 29.8%, 
and 24.1%, respectively. Amiodarone use and 
hospitalization decreased at 1-3 years (Marchlinski FE et 
al, J Am Coll Cardiol 2016;67:674-683).   
SORT OUT IV: Rate of Major Adverse Cardiovascu-
lar Events (MACE) at 5 Years is Lower in Patients 
Treated with Everolimus-Eluting Coronary Stents 
(EES) than in those Treated with Sirolimus-Coated 
Stents (SES), Attributable Largely to a Lower Rate of 
Late Stent Thrombosis  
Among 2,771 patients at 5-years, MACE occurred in 
14% and 17.4% in the EES and SES groups, respectively 
(hazard ratio - HR: 0.80, p = 0.02). The MACE rate did not 
differ significantly within the first year (HR: 0.96, p = 
0.79), but from years 1 through 5, the MACE rate was 
lower with EES (HR: 0.71; p = 0.006). Definite stent 
thrombosis was lower with EES (0.4%) than with SES 
(2%; HR: 0.18), with a lower risk of very late definite stent 
thrombosis in the EES group (0.2% vs 1.4%, respectively; 
HR: 0.16). When censoring the patients at the time of stent 
thrombosis, we found no significant differences between 
the 2 stent groups for MACE rates (HR: 0.89; p = 0.23), 
target lesion revascularization (HR: 0.90, p = 0.55), and MI 
(HR: 0.93; p = 0.72) (Jensen LO et al, J Am Coll Cardiol 
2016;67:751-762).   
Patients With PFO Who Develop Cryptogenic 
Ischemic Stroke Face Relatively Low Rates of 
Recurrent Cerebral Ischemic Events During Medical 
Therapy With or Without Device Closure, But Pooled 
Results of Randomized Trials Show Lower Stroke 
Rates With Percutaneously Implanted Device Closure 
Than With Medical Therapy Alone 
According with data on 2 devices (STARFlex, NMT 
Medical, Inc., Boston, MA & Amplatzer, AGA 
Medical/St. Jude Medical, St. Paul, MN) evaluated in 3 
trials in 2,303 patients, PFO closure was not significantly 
associated with the primary composite outcome (stroke, 
TIA, or death). The difference became significant after 
covariate adjustment (hazard ratio -HR: 0.68; p = 0.049). 
For stroke, all comparisons were statistically significant 
(HRs 0.58, p = 0.043). In analyses limited to the 2 disc 
occluder device trials, the effect of closure was not 
significant for the composite outcome, but was for the 
stroke outcome (HR: 0.39; p=0.013). Subgroup analyses 
did not identify significant heterogeneity of treatment 
effects. AF was more common in closure patients (Kent 
DM et al, J Am Coll Cardiol 2016;67:907-917).   
Patients With LQT3 Respond Incompletely to Beta-
Blockers and Face an Unfavorable Prognosis / 
Mexiletine Exerted Effective Antiarrhythmic Effects in 
this Cohort, Representing a Genotype-Specific 
Treatment for an Inherited Arrhythmogenic Substrate  
In 34 LQT3 patients (19 or 56% male; median age 22 
years at beginning of treatment with mexiletine; median 
QTc interval before therapy 509 ms; median duration of 
oral mexiletine 3 years; average daily dose 8 ± 0.5 mg/kg), 
mexiletine significantly shortened QTc (by 63 ± 6 ms; p < 
0.0001) and reduced the percentage of patients with 
arrhythmic events (from 22% to 3%; p = 0.031), the mean 
number of arrhythmic events per patient (from 0.43 ± 0.17 
to 0.03 ± 0.03; p = 0.027), and the annual rate of 
arrhythmic events (from 10.3% to 0.7%; p = 0.0097) 
(Mazzanti A et al, J Am Coll Cardiol 2016;67:1053-1058).   
PEGASUS-TIMI 54 Trial: In Patients With Prior MI 
on Extended Dual Antiplatelet Therapy, Ticagrelor 60 
mg bid Provides a Degree of Platelet Inhibition 
Comparable to that Achieved with 90 mg bid, which 
May Explain the Nearly Equivalent Efficacy of these 
Doses for Prevention of Recurrent Ischemic Events 
In 180 patients mean pre- and post-dose plasma levels 
of ticagrelor were 35% and 38% lower, respectively, with 
60 mg vs 90 mg bid. Both doses achieved high levels of 
platelet inhibition pre- and post-dose, with numerically 
slightly more variability with 60 mg: pre-dose PRU values 
were 59 ± 63 and 47 ± 43 for ticagrelor 60 and 90 mg, 
respectively (p=NS). High platelet reactivity (PRU >208) 
was rare with the 60-mg pre-dose and was absent post-
dose. Platelet reactivity pre- and post-dose, as measured by 
light transmittance aggregometry or vasodilator-
stimulated phosphoprotein assays, was numerically but not 
significantly lower with 90 mg than with 60 mg. Aspirin 
response was not affected by either dose (Storey RF et al, 
J Am Coll Cardiol 2016;67:1145-1154.).  
PREDICTS Study: Most Patients with Severe LV 
Dysfunction in the Acute Phase of MI Exhibit 
Improvement in LV Function 90 Days Later / Prior MI, 
Early VF or Cardiac Arrest, Peak Serum Troponin, 
and EF Early After Presentation are Predictors of 
Later Myocardial Recovery  
Among patients with ejection fraction (EF) ≤35% at the 
time of MI (n= 231), 43% had persistent EF≤35%, 31% 
had an EF of 36-49%, and 26% had an EF≥50% at 3 
months. Predictors for EF recovery to >35%, identified in 
a separate cohort (n= 236) included EF at presentation, 
length of stay, prior MI, lateral wall motion abnormality at 
presentation, and peak troponin. The model that best 
predicted recovery of EF to ≥50% included EF at 
presentation, peak troponin, prior MI, and presentation 
with ventricular fibrillation or cardiac arrest. After 
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predictors were transformed into point scores, the lowest 
point scores predicted a 9% and 4% probability of EF 
recovery to >35% and ≥50%, respectively, whereas 
profiles with the highest point scores predicted an 87% and 
49% probability of EF recovery to >35% and ≥50%, 
respectively (Brooks GC et al, J Am Coll Cardiol 
2016;67:1186-1196).   
BRUISE CONTROL INFECTION Study: Strategies to 
Reduce Pocket Hematomas in Device Implants, Such as 
Continuing Oral Anticoagulants Rather Than Bridging 
with Heparin, May Reduce Long-Term Infection Risk  
Among 659 patients the 1-year device-related infection 
rate was 2.4% (16/659). Infection occurred in 11% of 
patients (7/66) with previous clinically significant pocket 
hematoma (CSH) and in 1.5% (9/593) without CSH. CSH 
was the only independent predictor and was associated 
with a >7-fold increased risk of infection (hazard ratio: 7.7; 
p<0.0001). Empiric antibiotics upon development of 
hematoma did not reduce long-term infection risk 
(Essebag V et al, J Am Coll Cardiol 2016; 67:1300-1308).   
CHAMPION PHOENIX Trial: Cangrelor Reduced the 
Odds of Major Adverse Cardiovascular Events and 
Stent Thrombosis in Women and Men and Appeared 
to Offer Greater Net Clinical Benefit Than Clopidogrel 
Cangrelor, an IV ADP receptor antagonist leading to 
potent and reversible inhibition of platelet aggregation, 
given in a randomized way with clopidogrel to 11,145 
patients undergoing elective or urgent PCI (3051 or 28% 
women) reduced the odds of the primary end point (death, 
MI, revascularization, stent thrombosis) by 35% in women 
(odds ratio - OR, 0.65); and by 14% in men (OR, 0.86) 
compared with clopidogrel. Cangrelor reduced the odds of 
stent thrombosis by 61% in women (OR, 0.39) and 16% in 
men (OR, 0.84). The odds of severe bleeding were similar 
in women and men treated with cangrelor (0.3% vs 0.2% 
in women; 0.1% vs 0.1%, for men) vs clopidogrel. 
Cangrelor increased the odds of moderate bleeding in 
women (0.9% vs 0.3%, P=0.02), but not in men (0.2% vs 
0.2%, P=NS). The net clinical benefit favored cangrelor in 
both women (OR, 0.68) and men (OR, 0.87) (O’Donoghue 
ML et al, Circulation 2016;133: 248-255).   
National Trends in the Use of Cardiac 
Resynchronization Therapy (CRT) With or Without 
ICD : The Majority (86%) of Patients in this US Cohort 
Underwent Implantation of CRT-D  
Among 311,086 admissions for CRT implant, CRT-D 
was the most common device type (86.1%), including in 
patients ≥75 years of age with ≥5 comorbidities (75.5%). 
Multivariate predictors of CRT-D implant included: prior 
ventricular arrhythmia (rate ratio - RR, 1.14), ischemic 
heart disease (RR, 1.11), male gender (RR, 1.10), black 
race (RR, 1.06), and Northeast geographic region (RR, 
1.06). There was significant interhospital variation in the 
use of CRT-D (10–90 percentile range, 73%–98% CRT-
D) (Lindvall C et al, Circulation 2016; 133: 273-281).   
Sugar-Sweetened Beverage (SSB) Consumption is 
Associated With Change of Visceral Adipose Tissue 
(VAT) Over 6 Years of Follow-Up  
The quantity and quality of abdominal adipose tissue 
were measured using computed tomography in 1003 
participants (mean age 45.3 years, 45% women) at baseline 
and 6 years later. Higher SSB intake was associated with 
greater change in VAT volume (P trend<0.001). VAT 
volume increased by 658 cm3, 649 cm3, 707 cm3, and 852 
cm3 from nonconsumers (none to <1 serving/mo) to non-
daily (1 serving/mo to <1 serving/week, 1 serving/week to 
1 serving/d) to daily (≥1 serving/d) consumers. Higher 
SSB intake was also associated with greater decline of 
VAT attenuation (P trend=0.007); however, the 
association became nonsignificant after additional 
adjustment for VAT volume change. In contrast, diet soda 
consumption was not associated with change in abdominal 
adipose tissue (Ma J et al, Circulation 2016;133:370-7).   
Aerobic Interval Training (AIT) Reduces the Burden 
of Atrial Fibrillation (AF) in the Short Term 
Patients with nonpermanent AF were randomized to 
AIT (n=26) consisting of four 4-minute intervals at 85% to 
95% of peak heart rate 3 times a week for 12 weeks or to a 
control group (n=25) continuing regular exercise habits. 
Mean time in AF measured by an implanted loop recorder 
increased from 10.4% to 14.6% in the control group and 
was reduced from 8.1% to 4.8% in the exercise group 
(P=0.001). AF symptom frequency (P=0.006) and AF 
symptom severity (P=0.009) were reduced after AIT. AIT 
improved O2peak, left atrial and ventricular ejection 
fraction, quality-of-life, and lipid values compared with 
the control group. There was a trend toward fewer 
cardioversions and hospital admissions after AIT (Malmo 
V et al, Circulation 2016; 133: 466-473).   
The S-Wave in Lead I: A New Electrocardiographic 
Marker of Sudden Death in Brugada Syndrome (BS) 
During follow-up (48+38 months) of 347 patients 
(78.4% male; age 45+13.1 years) with spontaneous type 1 
BS but no history of cardiac arrest (91.1% initially 
asymptomatic, 5.2% with history of atrial fibrillation -AF, 
and 4% with history of syncope), 276 (79.5%) patients 
remained asymptomatic, 39 (11.2%) developed syncope, 
and 32 (9.2%) developed ventricular fibrillation (VF) / 
sudden cardiac death (SCD). Patients who developed 
VF/SCD had a lower prevalence of SCN5A gene 
mutations (p=0.009) and a higher prevalence of positive 
electrophysiological study results (p<0.0001), a family 
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history of SCD (p=0.03), and AF (p<0.0001). The most 
powerful marker for VF/SCD was a significant S-wave 
(>0.1 mV and/or >40 ms) in lead I. In multivariate 
analysis, the duration of S-wave in lead I >40 ms (hazard 
ratio: 39.1) and AF (hazard ratio: 3.7) were independent 
predictors of VF/SCD during follow-up (Calo L et al, J Am 
Coll Cardiol 2016;67:1427–1440).   
Pooled Analysis: In Patients With Brugada Syndrome 
(BS), Arrhythmias Induced With Programmed 
Ventricular Stimulation are Associated With Future 
Arrhythmia Risk / Induction With Fewer Extrastimuli 
is Associated With Higher Risk / However, Clinical 
Risk Factors are Important Determinants of 
Arrhythmia Risk, and Lack of Induction does not 
Necessarily Portend Low Risk, Particularly in Patients 
With High-Risk Clinical Features 
Analysis of 8 studies comprising 1312 patients with BS 
experiencing 65 cardiac events (median follow-up, 38.3 
months) indicated a total of 527 patients with inducible 
arrhythmias. Induction was associated with cardiac events 
during follow-up (hazard ratio, 2.66; P<0.001), with the 
greatest risk observed among those induced with single or 
double extrastimuli. Annual event rates varied by syncope 
history, presence of spontaneous type 1 ECG pattern, and 
arrhythmia induction. The lowest risk occurred in 
individuals without syncope and with drug-induced type 1 
patterns (0.23% for no induced arrhythmia with up to 2 
extrastimuli; 0.45% for induced arrhythmia), and the 
highest risk occurred in individuals with syncope and 
spontaneous type 1 pattern (2.55% for no induced 
arrhythmia; 5.60% for induced arrhythmia) (Sroubek J et 
al, Circulation 2016; 133: 622-630).   
Brugada Syndrome is Common in Women (42% in this 
Database) / Clinical Presentation is Less Severe than 
Men, With More Asymptomatic Status and Less 
Spontaneous Type I ECG and Prognosis is More 
Favorable, With an Event Rate of 0.7% Year. 
However, Women With Sudden Cardiac Death (SCD) 
or Previous Sinus Node Dysfunction (SND) are at 
Higher Risk of Arrhythmic Events 
Among 228 women presenting with spontaneous or 
drug-induced Brugada type I ECG (age 41.5±17.3 years; 
clinical presentation with SCD in 6 or 2.6%, syncope in 51 
or 22.4% and 171 or 75% asymptomatic) compared with 
314 men with the same diagnosis, spontaneous type I ECG 
was less common (7.9% vs 23.2%, p<0.01) and less 
ventricular arrhythmias were induced during programmed 
electrical stimulation (5.5% vs 22.3%, p<0.01). An ICD 
was implanted in 64 women (28.1%). During follow-up of 
73.2±56.2 months, 7 patients developed arrhythmic events, 
constituting an event rate of 0.7% per year (as compared 
with 1.9% per year in men, p=0.02). Presentation as SCD 
or SND was risk factor significantly associated with 
arrhythmic events (hazard risk -HR 25.4 and 9.1) (Sieira J 
et al, Heart 2016; 102:452-458).   
WOSCOPS: In High-Risk Men With Elevated LDL 
Cholesterol but Without a History of MI, Statin 
Therapy for 5 Years was Associated With a Legacy 
Benefit, With Improved Survival and a Substantial 
Reduction in CV Disease Outcomes Over 20-Years 
Among 6595 men, randomized to receive pravastatin 
40 mg/d or placebo for an average of 4.9 years, analysis of 
major incident events over 20 years indicated that men 
allocated to pravastatin had reduced all-cause mortality 
(hazard ratio-HR, 0.87; P=0.0007), attributable mainly to 
a 21% decrease in cardiovascular (CV) death (HR, 0.79; 
P=0.0004). There was no difference in non-CV or cancer 
death rates between groups. Cumulative hospitalization 
event rates were lower in the statin-treated arm: by 18% 
for any coronary event (P=0.002), by 24% for myocardial 
infarction (MI) (P=0.01), and by 35% for heart failure 
(P=0.002). There were no significant differences between 
groups in hospitalization for non-CV causes (Ford I et al, 
Circulation 2016;133:1073-1080).   
Two-Year Outcomes of Surgery for Severe Ischemic 
Mitral Regurgitation (MR): No Significant Difference 
Between Mitral-Valve Repair and Replacement in LV 
Reverse Remodeling or Survival / MR Recurred More 
Frequently in the Repair Group, With More Heart-
Failure–Related Adverse Events and CV Admissions 
In patients (n=251) with severe ischemic MR, 
randomized to mitral-valve (MV) repair or replacement, at 
2 years, LV end-systolic volume (LVESV) was 52.6±27.7 
ml/m2 with MV repair and 60.6±39.0 ml/m2 with MV 
replacement. Two-year mortality was 19% in the repair 
and 23.2% in the replacement group (hazard ratio, 0.79; 
P=0.39). The rate of recurrence of moderate or severe MR 
at 2 years was higher in the repair than in the replacement 
group (58.8% vs 3.8%, P<0.001). There were no 
significant between-group differences in serious adverse 
events and overall readmissions, but patients in the repair 
group had more serious adverse events related to heart 
failure (P=0.05) and cardiovascular (CV) re-admissions 
(P=0.01). There was a trend toward greater quality of life 
improvement in the replacement group (P=0.07) 
(Goldstein D et al, N Engl J Med 2016; 374:344-353).  
The Leadless Intracardiac Transcatheter Pacemaker, 
Compared to Historical Conrols, Met the Prespecified 
Safety and Efficacy Goals/ It Had a Safety Profile 
Similar to that of a Transvenous System With Low and 
Stable Pacing Thresholds 
The Micra transcatheter pacemaker was successfully 
implanted in 719 of 725 patients (99.2%). The primary 
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safety end point (freedom from major complications) was 
96% (P<0.001 for the comparison with the safety 
performance goal of 83%); there were 28 major 
complications in 25 of 725 patients, and no dislodgements, 
all fewer compared to the control patients (hazard ratio, 
0.49; P=0.001). The rate of the primary efficacy end point 
(percentage of patients with low and stable pacing capture 
thresholds at 6 months, i.e. ≤2.0 V at a pulse width of 0.24 
ms and an increase of ≤1.5 V from the time of 
implantation) was 98.3% (P<0.001 for the comparison 
with the efficacy performance goal of 80%) among 292 of 
297 patients with paired 6-month data (Reynolds D et al, 
N Engl J Med 2016; 374:533-541).   
Coronary Artery Surgery: The Administration of 
Preoperative Aspirin Resulted in Neither a Lower Risk 
of Death or Thrombotic Complications Nor a Higher 
Risk of Bleeding Compared With Placebo 
Patients (n=2100) who were scheduled to undergo 
coronary artery surgery and were at risk for perioperative 
complications were randomly assigned to receive 100 mg 
of aspirin (n=1047) or placebo (n=1053) preoperatively. A 
primary outcome event (death and thrombotic 
complications, i.e. nonfatal myocardial infarction, stroke, 
pulmonary embolism, renal failure, or bowel infarction 
within 30 days after surgery) occurred in 202 patients in 
the aspirin group (19.3%) and in 215 patients in the 
placebo group (20.4%) (relative risk, 0.94; P=NS). Major 
hemorrhage leading to reoperation occurred in 1.8% of 
patients in the aspirin group and in 2.1% of patients in the 
placebo group (P=NS), and cardiac tamponade occurred at 
rates of 1.1% and 0.4%, respectively (P=0.08) (Myles PS 
et al, N Engl J Med 2016; 374:728-737).  
 
ACT I Trial: In Asymptomatic Patients With Severe 
Carotid Stenosis Who were not at High Risk for 
Surgical Complications, Stenting was Noninferior To 
Endarterectomy at 1 Year / At 5 Years, there were no 
Significant Differences Between the Study Groups in 
Rates of Stroke and Survival  
Among 1453 asymptomatic patients <79 years with 
severe carotid stenosis, stenting with embolic protection 
was noninferior to endarterectomy with regard to the 
primary composite end point (death, stroke, or MI within 
30 days) (event rate, 3.8% and 3.4%, respectively; P=0.01 
for noninferiority). The rate of stroke or death within 30 
days was 2.9% in the stenting group and 1.7% in the 
endarterectomy group (P=NS). From 30 days to 5 years 
after the procedure, the rate of freedom from ipsilateral 
stroke was 97.8% in the stenting group and 97.3% in the 
endarterectomy group (P=NS), and overall survival rates 
were 87.1% and 89.4%, respectively (P=0.21). The 
cumulative 5-year rate of stroke-free survival was 93.1% 
in the stenting group and 94.7% in the endarterectomy 
group (P=NS) (Rosenfield K et al, N Engl J Med 2016; 
374:1011-1020).  
 
CREST 10-Year Results: No Significant Difference 
Between Patients Who Underwent Stenting and Those 
With Endarterectomy in the Risk of Periprocedural 
Stroke, MI, or Death and Subsequent Ipsilateral Stroke  
Among 2502 patients, there was no significant 
difference in the rate of the primary composite end point 
(stroke, MI or death) between the stenting group (11.8%) 
and the endarterectomy group (9.9%) over 10 years of 
follow-up (hazard ratio - HR, 1.10). Postprocedural 
ipsilateral stroke over the 10-year follow-up occurred in 
6.9% of the patients in the stenting group and in 5.6% of 
those in the endarterectomy group; the rates did not differ 
significantly between the groups (HR, 0.99). No 
significant between-group differences with respect to 
either end point were detected when symptomatic patients 
and asymptomatic patients were analyzed separately (Brott 
DG et al, N Engl J Med 2016; 374:1021-1031).  
 
Warning Symptoms Frequently Occur Before Sudden 
Cardiac Arrest (SCA), But Most are Ignored / 
Emergent Medical Care Call Was Associated With 
Survival in Patients With Symptoms  
Of 839 patients with SCA and comprehensive 
assessment of symptoms (mean age, 52.6 years; 75% 
men), 430 (51%) had warning symptoms (50% of men & 
53% of women), mainly chest pain and dyspnea. In most 
symptomatic patients (93%), symptoms recurred within 
the 24 hours preceding SCA. Only 81 patients (19%) called 
emergency medical services (EMS) to report symptoms 
before SCA; these persons were more likely to be patients 
with a history of heart disease (P< 0.001) or continuous 
chest pain (P< 0.001). Survival when EMS was called in 
response to symptoms was 32.1% compared with 6% in 
those who did not call (P< 0.001) (Marijon E et al, Ann 
Intern Med 2016;164:23-29.).  
 
VISION study: Among Patients Undergoing Non-
Cardiac Surgery, Pre-Operative Statin Therapy 
Conferred a Lower Risk of Cardiovascular Outcomes 
at 1 Month  
Among 15,478 patients (>45 years) having in-patient 
non-cardiac surgery, analysis of a matched population of 
2845 patients (18.4%) treated with a statin and 4492 (29%) 
controls, indicated that the pre-operative use of statins was 
associated with lower risk of the primary outcome, a 
composite of all-cause mortality, myocardial injury after 
non-cardiac surgery (MINS), or stroke at 30 days (relative 
risk - RR, 0.83; P = 0.007). Statins were also associated 
with a significant lower risk of all-cause mortality (RR, 
0.58; P = 0.003), cardiovascular mortality (RR, 0.42; P = 
0.004), and MINS (RR, 0.86; P = 0.02). There were no 
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significant differences in the risk of MI or stroke 
(Berwanger O et al, Eur Heart J 2016; 37: 177-185).  
 
Effect of Timing of Pre-operative Discontinuation of 
Ticagrelor/Clopidogrel on CABG-Related Major 
Bleeding: Discontinuation 3 Days (vs 5 Days) Before 
Surgery did not Increase the Incidence of Major 
Bleeding Complications with Ticagrelor, but Increased 
the Risk with Clopidogrel  
Among all acute coronary syndrome patients in Sweden 
on dual antiplatelet therapy with aspirin and ticagrelor (n 
= 1266) or clopidogrel (n = 978) who underwent CABG, 
the incidence of major bleeding complications was 38 and 
31%, respectively, when ticagrelor/clopidogrel was 
discontinued <24 h before surgery. Within the ticagrelor 
group, there was no significant difference between 
discontinuation 3–5 or >5 d before surgery (odds ratio - 
OR 0.93, P=NS). In contrast, clopidogrel-treated patients 
had a higher incidence when discontinued 3–5 vs >5 d 
before surgery (OR 1.71, P = 0.033). The overall incidence 
of major bleeding complications was lower with ticagrelor 
(12.9 vs 17.6%, adjusted OR 0.72, P = 0.012) (Hansson 
EC et al, Eur Heart J 2016; 37: 189-197).  
 
Significance of ECG Recording in High Intercostal 
Spaces (HICS) in Patients With Early Repolarization 
Syndrome (ERS): 16% of the Patients Diagnosed With 
ERS Under the Previous Criteria were Actually 
Brugada Syndrome (BS) Patients With Inferolateral 
ER and a Type 1 Brugada Pattern-ECG Only in HICS  
Among 56 patients showing inferolateral early 
repolarization (ER) in the standard ECG and spontaneous 
idiopathic ventricular fibrillation (VF) who underwent 
drug provocation tests by sodium channel blockade with 
right precordial ECG (V1–V3) recordings in the 2nd–4th 
intercostal spaces, and after 18 patients showing type 1 
Brugada pattern-ECG in the standard ECG were excluded, 
38 patients (34 males, mean age; 40.4 ± 13.6 years) were 
classified into 4 groups: group A (n = 6;16%): patients with 
ER and type 1 Brugada pattern-ECG only in HICS; group 
B (n = 5;13%): ERS with non-type 1 Brugada pattern-ECG 
only in HICS; group C (n = 8;21%): ERS with non-type 1 
Brugada pattern-ECG in the standard ECG; and group D 
(n = 19;50%): ERS only, spontaneously or after drug 
provocation test. During follow-up of 9.2 ± 4.6 years, the 
rate of VF recurrence was significantly higher in groups A 
(4/6:67%), B (4/5:80%), and C (4/8:50%) compared with 
D (2/19:11%) (A, B, and C vs D, P < 0.05) (Kamakura T 
et al, Eur Heart J 2016; 37: 630-637).  
 
EAST-AF Trial: Short-Term Use of Antiarrhythmic 
Drugs (AAD) for 3 Months Following AF Ablation 
Reduced Recurrent AF During the Treatment Period, 
But it did not Lead to Improved Clinical Outcomes at 
1 Year / Early Arrhythmia Recurrence was Strongly 
Associated With Late Arrhythmia Recurrence  
Among 2038 patients who had undergone radio-
frequency catheter ablation for paroxysmal, persistent, or 
long-lasting AF, randomly assigned to either 90-day use of 
AAD (n=1016) or control (n=1022) group, those assigned 
to AAD were associated with higher event-free rate from 
recurrent AF when compared with the control group during 
the treatment period of 90 days (59 and 52.1%, 
respectively; hazard ratio - HR 0.84; P = 0.01). However, 
there was no significant difference in the 1-year event-free 
rates (Kaitani K et al, Eur Heart J 2016; 37: 610-618).  
 
SEPTAL CRT Study: Septal RV Pacing in CRT is 
Similar to Apical RV Pacing for LV Reverse 
Remodelling at 6 Months With no Difference in the 
Clinical Outcome  
Patients (n=263, age = 63.4 ± 9.5 years) were randomly 
assigned to right ventricular septal (RVS) (n=131) vs 
apical (RVA) (n=132) pacing. Left ventricular end-systolic 
volume (LVESV) reduction between baseline and 6 
months was not different between the two groups. RVS 
pacing was not non-inferior to RVA pacing with regard to 
LVESV reduction (average difference = −4.06 mL; P = 
0.006 with a −20 mL non-inferiority margin). The 
percentage of ‘echo-responders’ defined by LVESV 
reduction >15% between baseline and 6 months was 
similar in both groups (50%) with no difference in the time 
to first heart failure hospitalization or death (P=NS). 
Procedural or device-related serious adverse events 
occurred in 68 patients (RVS = 37) with no difference 
between the two groups (P = NS) (Leclercq C et al, Eur 
Heart J 2016; 37: 473-483).  
 
BIOSOLVE II: Implantation of the DREAMS 2G 
Absorbable Stent in De-Novo Coronary Lesions is 
Feasible, With Favorable Safety and Performance 
Outcomes at 6 Months 
In 123 patients with 123 coronary target lesions 
receiving the novel absorbable stent, at 6 months, mean in-
segment late lumen loss was 0.27+0.37 mm, and 
angiographically discernable vasomotion was documented 
in 20 (80%) of 25 patients. Intravascular ultrasound 
showed a preservation of the scaffold area with a low mean 
neointimal area, and optical coherence tomography did not 
detect any intraluminal mass. Target lesion failure 
occurred in 4 (3%) patients: 1 (<1%) died from cardiac 
death, 1 (<1%) had periprocedural MI, and 2 (2%) patients 
needed clinically driven target lesion revascularization. No 
definite or probable scaffold thrombosis was observed 
(Haude M et al, Lancet 2016; 387:31–39).  
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Systematic Review and Meta-Analysis: Intensive Blood 
Pressure (BP) Lowering Provided Greater Vascular 
Protection Than Standard Regimens  
Among 44,989 participants (19 trials), 2496 major 
cardiovascular (CV) events were recorded at a mean of 3.8 
years. Patients in the more intensive BP-lowering group 
(mean BP 133/76 mmHg, compared with 140/81 mmHg in 
the less intensive treatment group) had relative risk (RR) 
reductions for major CV events (14%), MI (13%), stroke 
(22%), albuminuria (10%), and retinopathy progression 
(19%). However, more intensive treatment had no clear 
effects on heart failure (15%), CV death (9%), total 
mortality (9%), or end-stage kidney disease (10%). The 
reduction in major CV events was consistent across patient 
groups, and additional BP lowering had a benefit even 
when systolic BP was <140 mmHg. The absolute benefits 
were greatest in trials in which all enrolled patients had 
vascular or renal disease, or diabetes. Serious adverse 
events associated were only reported by 6 trials and had an 
event rate of 1.2%/year in the intensive vs 0.9% in the less 
intensive treatment group (RR 1.35). Severe hypotension 
was more frequent in the more intensive treatment regimen 
(RR 2.68, p=0.015), but the absolute excess was small 
(0.3% vs 0.1% per person-year for the duration of follow-
up) (Xie X et al, Lancet 2016; 387: 435–443).  
 
Blood Pressure (BP) Lowering Significantly Reduces 
Vascular Risk Across Various Baseline BP Levels and 
Comorbidities / Results Provide Strong Support for 
Lowering BP to Systolic BPs <130 mmHg and Treating 
Individuals With a History of Cardiovascular (CV) 
Disease, Coronary Disease, Stroke, Diabetes, Heart 
Failure, and Chronic Kidney Disease  
Among 613,815 participants (123 studies) every 10 
mmHg reduction in systolic BP significantly reduced the 
risk of major CV disease events (relative risk - RR 0.80), 
coronary disease (0.83), stroke (0.73), and heart failure 
(0.72), which led to a significant 13% reduction in all-
cause mortality (0.87). However, the effect on renal failure 
was not significant (0.95). Similar proportional risk 
reductions (per 10 mm Hg lower systolic BP) were noted 
in trials with higher and trials with lower mean baseline 
systolic BP (all ptrend>0.05). There was no clear evidence 
that proportional risk reductions in major CV disease 
differed by baseline disease history, except for diabetes 
and chronic kidney disease, for which smaller, but 
significant, risk reductions were detected. β blockers were 
inferior to other drugs for prevention of major CV disease 
events, stroke, and renal failure. Calcium channel blockers 
(CCBs) were superior to other drugs for the prevention of 
stroke. For the prevention of heart failure, CCBs were 
inferior and diuretics were superior to other drug classes 
(Ettehad D et al, Lancet 2016; 387: 957–967).  
 
TOTAL Trial, 1-Year Follow-Up: Routine Thrombus 
Aspiration During PCI for STEMI did not Reduce 
Longer-Term Clinical Outcomes and Might be 
Associated With an Increase in Stroke  
Among 10,064 patients (5035 thrombectomy/ 5029 PCI 
alone), the primary outcome at 1 year occurred in 8% in 
the thrombectomy group and 8% in the PCI alone group. 
Cardiovascular death within 1 year occurred in 4% in each 
group. The key safety outcome, stroke within 1 year, 
occurred in 1.2% in the thrombectomy group and 0.7% in 
the PCI alone group (hazard ratio-HR 1.66, p=0·015) 
(Jolly SS et al, Lancet 2016; 387 (10014):127-135).  
 
After Eighty Study: In Patients Aged >80 Years With 
NSTEMI or Unstable Angina, an Invasive is Superior 
to a Conservative Strategy  
Among patients aged >80 years with NSTEMI or 
unstable angina, at a median of 1.53 years, the primary 
outcome (MI, need for urgent revascularization, stroke and 
death) occurred in 93/229 (40.6%) patients in the invasive 
and 140/228 (61.4%) patients in the conservative group 
(hazard ratio-HR 0.53, p=0.0001). HRs were 0.52 
(p=0.0010) for MI, 0.19 (p=0.0010) for need for urgent 
revascularization, 0.60 (p=NS) for stroke, and 0.89 (p=NS) 
for death. The invasive group had 4 (1.7%) major and 23 
(10%) minor bleeding complications and the conservative 
group 4 (1.8%) major & 16 (7%) minor bleeding complica-
tions (Tegn N et al, Lancet 2016;387:1057–1065).  
 
Important Review and Other Articles  
 
2015 ACC/AHA/SCAI Focused Update on Primary PCI for Patients 
With STEMI (Levine GN et al, J Am Coll Cardiol 2016;67:1235-1250), 
Exercise and cardiovascular events (Eijsvogels TMH et al, J Am Coll 
Cardiol 2016;67:316-329), Natriuretic peptide testing in heart failure 
(Francis GS et al, J Am Coll Cardiol 2016;67:330-337), Subcutaneous 
ICD (Lewis GF & Gold MR, J Am Coll Cardiol 2016;67:445-454), 
Testosterone and cardiovascular disease (Kloner RA et al, J Am Coll 
Cardiol. 2016;67:545-557), Pulmonary embolism management 
(Konstantinides S et al, J Am Coll Cardiol 2016;67:976-990), QRS 
duration vs morphology in CRT (Poole JE et al, J Am Coll Cardiol 
2016;67:1104-1117), ICD lead failure and management (Swerdlow CD 
et al, J Am Coll Cardiol 2016;67:1358-1368), Surgery for aortic 
dilatation in bicuspid aortic valves (Hiratzka LF et al, Circulation 
2016;133:680-686), Acute MI in women (Mehta LS et al, Circulation 
2016;133:916-947), Sudden death in the young (Ackerman M et al, 
Circulation 2016;133:1006-1026), Combined angiotensin receptor 
antagonism and neprilysin inhibition (Hubers SA & Brown NJ, 
Circulation 2016;133:1115-1124), Statin associated autoimmune 
myopathy (Mammen AL, N Engl J Med 2016;374:664-669 ), Special 
Issue on the 2015 ESC/ERS Guidelines for the diagnosis and treatment 
of pulmonary hypertension (Eur Heart J 2016 Jan; 37(1)), 2015 ESC 
Guidelines for the management of ACS without persistent ST-segment 
elevation (Eur Heart J 2016; 37:267-315), TAVI (Hamm CW et al, Eur 
Heart J 2016; 37: 803-810), Catheter ablation of VT (Tanawuttiwat T 
et al, Eur Heart J 2016;37:594-609), Infective endocarditis (Cahill TJ 
& Prendergast BD, Lancet 2016; 387(10021): 882–893), Cardiac 
sarcoidosis (Kusano KF & Satomi K, Heart 2016;102:184-190) .  
 
